Improve Safety in Polymedication by Managing Drug-Drug-Gene Interactions

Informazioni relative al progetto

SafePolyMed

ID dell’accordo di sovvenzione: 101057639

DOI

10.3030/101057639

Progetto chiuso

Data della firma CE 23 Maggio 2022

Data di avvio 1 Giugno 2022

Data di completamento 31 Agosto 2026

Finanziato da

• Health

Costo totale

€ 5 650 444,56

Contributo UE

€ 5 650 442,81

Coordinato da

UNIVERSITAT DES SAARLANDES
Germany

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Other (1)

First version of MMC deployed

Websites, patent fillings, videos etc. (2)

Public Project Website
Audio-visual material

Documents, reports (7)

Selection of clinically relevant compounds
English-Estonian dictionary
Content for the training curriculum for empowerment of patients in pharmacology and drug safety
Specifications of a core set of Safety PROM for the implementation in WP3 (medication management system) and WP5 (piloting a case study)
First model-based dose adjustments
Design and implementation of the SafePolyMed platform for the analysis of the retrospective data
Patient engagement Hub: setup of a priority setting network of different patient organisations

Pubblicazioni

Peer reviewed articles (13)

Side effects in hypertension treatment: a pharmacogenomic analysis

Autori: Felix Vaura, Kristi Krebs, Tuomo Kiiskinen, Joel Rämö, Max Tamlander, null null, Andres Metspalu, Tõnu Esko, Reedik Mägi, Mait Metspalu, Mari Nelis, Georgi Hudjashov, Simone Rubinacci, Lili Milani, Samuli Ripatti
Pubblicato in: European Heart Journal, 2026, ISSN 0195-668X
Editore: Oxford University Press (OUP)
DOI: 10.1093/EURHEARTJ/EHAG575

Cognitive function in the context of pharmacogenetic CYP2D6 variability and anticholinergic burden in older adults – results from the ActiFE study

Autori: Linda Lorenz, Judith Berres, Michael D Denkinger, Dietrich Rothenbacher, Stefanie Braig, Dhayana Dallmeier, Katja S Just
Pubblicato in: European Journal of Clinical Pharmacology, Numero 82, 2026, ISSN 0031-6970
Editore: Springer Science and Business Media LLC
DOI: 10.1007/S00228-026-04155-Y

A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions

Autori: Christina Kovar, Helena Leonie Hanae Loer, Simeon Rüdesheim, Laura Maria Fuhr, Fatima Zahra Marok, Dominik Selzer, Matthias Schwab, Thorsten Lehr
Pubblicato in: CPT: Pharmacometrics & Systems Pharmacology, Numero 13, 2024, ISSN 2163-8306
Editore: Wiley
DOI: 10.1002/PSP4.13146

Very strong correlations of metoprolol- and solanidine-derived metabolic ratios in a real-world cohort with a stable metoprolol drug regimen

Autori: Jens Andreas Sarömba, Berkan Kurt, Alessandra Antwerpen, Konstantin Rex, Anna Giacin, Justus Bornemann, Kaan Aygar, Marieke Mertens, Dirk Müller-Wieland, Edgar Dahl, Nikolaus Marx, Florian Kahles, Justyna Wozniak, Jule Neiß, Dominik Krzoska, Julia C. Stingl, Julian Peter Müller, Katja S. Just
Pubblicato in: Frontiers in Pharmacology, Numero 17, 2026, ISSN 1663-9812
Editore: Frontiers Media SA
DOI: 10.3389/FPHAR.2026.1812007

Extracting and Classifying Drug Discontinuations From Estonian Electronic Health Records: Development and Validation Study

Autori: Hendrik Šuvalov, Nikita Umov, Maria Malk, Markus Haug, Sven Laur, Marek Oja, Sirli Tamm, Sulev Reisberg, Jaak Vilo, Raivo Kolde
Pubblicato in: Journal of Medical Internet Research, Numero 28, 2026, ISSN 1438-8871
Editore: J Med Internet Res
DOI: 10.2196/86183

A Comprehensive <scp>CYP2D6</scp> Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development

Autori: Simeon Rüdesheim, Helena Leonie Hanae Loer, Denise Feick, Fatima Zahra Marok, Laura Maria Fuhr, Dominik Selzer, Donato Teutonico, Annika R. P. Schneider, Juri Solodenko, Sebastian Frechen, Maaike van der Lee, Dirk Jan A. R. Moes, Jesse J. Swen, Matthias Schwab, Thorsten Lehr
Pubblicato in: Clinical Pharmacology &amp; Therapeutics, Numero 117, 2025, ISSN 0009-9236
Editore: Wiley
DOI: 10.1002/CPT.3604

Text-based approach for detecting cases of ADEs from EHRs of participants of the Estonian Biobank

Autori: Dage Särg, Kairit Sirts, Kristi Krebs, Markus Tamm, Alise Metsküla, Marek Oja, Sven Laur, Jaak Vilo, Lili Milani
Pubblicato in: Informatics in Medicine Unlocked, Numero 59, 2025, ISSN 2352-9148
Editore: Elsevier BV
DOI: 10.1016/J.IMU.2025.101701

Assessment of Substrate Status of Drugs Metabolized by Polymorphic Cytochrome P450 (CYP) 2 Enzymes: An Analysis of a Large-Scale Dataset

Autori: Jakob Sommer; Justyna Wozniak; Judith Schmitt; Jana Koch; Julia C. Stingl; Katja S. Just
Pubblicato in: Biomedicines, Numero 12, 2024, ISSN 2227-9059
Editore: MDPI
DOI: 10.18154/RWTH-CONV-253072

Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical Implementation

Autori: R. Mosch, M. van der Lee, H.J. Guchelaar, J.J. Swen
Pubblicato in: Annual Review of Pharmacology and Toxicology, Numero 65, 2025, ISSN 0362-1642
Editore: Annual Reviews
DOI: 10.1146/ANNUREV-PHARMTOX-061724-080935

Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6

Autori: Kristi Krebs, Laura Birgit Luitva, Anette Caroline Kõre, Raul Kokasaar, Maarja Jõeloo, Georgi Hudjashov, Kadri Maal, Elisabet Størset, Birgit Malene Wollmann, Liis Karo-Astover, Krista Fischer, Estonian Biobank Research Team, Volker M. Lauschke, Magnus Ingelman-Sundberg, Espen Molden, Alar Irs, Kersti Oselin, Jana Lass, Lili Milani
Pubblicato in: npj Genomic Medicine, Numero 11, 2026, ISSN 2056-7944
Editore: Springer Science and Business Media LLC
DOI: 10.1038/S41525-025-00549-6

Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases

Autori: Tuomo Kiiskinen, Pyry Helkkula, Kristi Krebs, Juha Karjalainen, Elmo Saarentaus, Nina Mars, Arto Lehisto, Wei Zhou, Mattia Cordioli, Sakari Jukarainen, Joel T. Rämö, Juha Mehtonen, Kumar Veerapen, Markus Räsänen, Sanni Ruotsalainen, Mutaamba Maasha, F
Pubblicato in: Nature Medicine, Numero 29, 2023, ISSN 1078-8956
Editore: Nature Medicine (Nat Med)
DOI: 10.1038/s41591-022-02122-5

Genetic influences on antidepressant side effects: a CYP2C19 gene variation and polygenic risk study in the Estonian Biobank

Autori: Hanna Maria Kariis, Dage Särg, Kristi Krebs, Maarja Jõeloo, Kadri Kõiv, Kairit Sirts, null null, Georgi Hudjashov, null null, Dage Särg, Maris Alver, Kelli Lehto, Lili Milani
Pubblicato in: European Journal of Human Genetics, Numero 33, 2025, ISSN 1018-4813
Editore: Springer Science and Business Media LLC
DOI: 10.1038/S41431-025-01894-X

Physiologically based pharmacokinetic modeling of imatinib and <i>N</i>‐desmethyl imatinib for drug–drug interaction predictions

Autori: Helena Leonie Hanae Loer, Christina Kovar, Simeon Rüdesheim, Fatima Zahra Marok, Laura Maria Fuhr, Dominik Selzer, Matthias Schwab, Thorsten Lehr
Pubblicato in: CPT: Pharmacometrics &amp; Systems Pharmacology, Numero 13, 2024, ISSN 2163-8306
Editore: Wiley
DOI: 10.1002/PSP4.13127